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Background: Vitamin D is believed to play an important role outside the endocrine system in the regulation of the
immune system, and in cellular proliferation and differentiation. The aim of the study was to investigate the impact
of vitamin D levels on innate immunity.
Methods: Participants for this prospective, longitudinal study were recruited amongst otherwise healthy staff of a
large hospital in Victoria, Australia. Those fulfilling the inclusion criteria, including a vitamin D level of <50 nmol/L,
were supplemented. Using flow cytometry, expression of the innate immune receptors TLR2, TLR4 and CD86 was
measured on peripheral blood mononuclear cells (PBMCs) collected prior to vitamin D treatment and then at 1 and
3 months. Additonally, PBMCs at each timepoint were stimulated with specific TLR ligands and resultant
supernatants were assayed for the cytokines TNFα, IL-6, IFN-α and IP-10.
Results: In participants whose vitamin D level was >100 nmol/L post supplementation (n=11), TLR2 expression on
PBMCs increased significantly, with no change noted in TLR4 or CD86 expression. Stimulation of vitamin D deficient
samples with TLR ligands produced a number of proinflammatory cytokines, which were significantly reduced upon
vitamin D normalisation. In patients whose levels returned to a deficient level at 3 months despite ongoing low-level
supplementation, an increase in the pro-inflamamtory state returned. This suggests that vitamin D may play an
important role in ensuring an appropriate baseline pro-inflammatory state.
Conclusions: This ex-vivo pilot study adds clinical evidence supporting a possibly important role for vitamin D in innate
immunity. If confirmed, this unique clinical study has potentially significant implications for the treatment of a variety of
inflammatory conditions, where achieving optimal vitamin D levels may help reduce inflammation.
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Vitamin D’s importance outside the endocrine system
is being increasingly recognized, in particular in the
regulation of hormone secretion and the immune system,
as well as cellular proliferation and differentiation [1].
Consequently, vitamin D deficiency has been linked to
an increased risk of a number of conditions, both in-
fectious and non-infectious, including Mycobacterium
tuberculosis, cardiovascular disease, asthma, varying* Correspondence: kv@unimelb.edu.au
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reproduction in any medium, provided the ormalignancies and autoimmune conditions such as mul-
tiple sclerosis and type I diabetes [2-5].
The role of vitamin D with respect to adaptive im-
munity has been recognised for over 25 years, where it
predominantly exhibits an inhibitory or suppressive
effect on T-cell activation and proliferation, especially
of T helper-1 cells (TH1), which produce IFN-γ and
lead to activation of macrophages [1,2,6]. However, it
also favours a T helper-2 (TH2) response by the regulation
of the secretion of other cytokines, resulting in increased
production of IL-4, IL-5 and IL-10 by T-cells [1,2,7,8].
More recently, there is evidence that vitamin D may play
an important role in innate immunity. The innate immune
system involves the activation of transmembrane patternLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that interact with specific pathogen proteins [1,2]. This
in turn leads to release of antimicrobial peptides and
the subsequent killing of the organism [1,2]. TLRs are
also instrumental in activating adaptive immunity [9].
TLR2 senses lipopeptides from bacteria and leads to
activation of NF-κB and induction of cytokine production
and release [10,11]. TLRs also lead to expression of T-cell
costimulatory molecules CD80 and CD86 via induction
of IFNβ [11,12]. These molecules are expressed on anti-
gen presenting cells and are also important for B-cell
activation [13]. Both TLR2 and TLR4 on monocytes
have been shown to be downregulated by the immuno-
modulatory effect of vitamin D [14]. TLR2 has also been
shown to be important in response to vaccines, with
TLR2-knock out mice having reduced responses to vac-
cination with lipopeptides [11]. These studies prompted
us to assess further the role of vitamin D on the innate
immune system, specifically TLR2.
In this prospective, longitudinal pilot study, we aimed
to explore whether vitamin D deficiency results in an
increased innate inflammatory signature and enhanced
TLR activation. No prospective data with repeated mea-
sures of vitamin D levels and markers of innate immun-
ity are present in the published literature.
Methods
Study design and subjects
This study was designed as a pilot prospective longitu-
dinal study in which otherwise healthy vitamin D defi-
cient participants were followed over a period of three
months after supplementation. Following approval from
the institutional ethics committee, participants were
recruited within the Southern Health Care Network,
Victoria, Australia. Recruitment occurred at the end of
Winter to maximize the chance of vitamin D deficiency.
After obtaining informed consent, participants went
on to have further testing if they met the basic screeningFigure 1 Summary of study protocol.inclusion criteria, which included: being male (between
18 and 50 years of age) or female (>18, with menstru-
ation within the last year) and having a Body Mass Index
(BMI) between 20 and 30. Vitamin deficiency was de-
fined as 25-OH-vitamin D levels of <50 nmol/L. Partici-
pants were also screened for conditions that may affect
vitamin D metabolism and levels including a history of
renal, hepatic, thyroid, parathyroid, coeliac or other
malabsorptive diseases. Those with any such conditions
were excluded from the study. Those with chronic
diseases, or conditions which may be associated with
elevated inflammatory states, were also excluded, includ-
ing diabetes, chronic infections such as chronic hepatitis
and Human Immunodeficiency Virus infections, auto-
immune conditions, asthma or cardiovascular diseases.
Participants were also screened on history for symptoms
suggestive of active infection.
A summary of the study protocol is outlined in Figure 1.
Vitamin D supplementation
Initially, all participants had baseline bloods measured.
Those who were vitamin D deficient were then loaded
with a single tablet of 50,000 units of vitamin D, given
daily for 10 days. This formulation had not at the time
been approved in Australia. However, it had received
ethics approval in our hospital for use in the tuberculosis
clinic and had been approved for routine use in other ju-
risdictions overseas. After loading, subjects went on to a
maintenance regimen, which included one tablet (50,000
units) monthly. This continued for a total of 3 months
of therapy, with a total of two monthly maintenance
doses. After this period, with the completion of the
study, participants were encouraged to continue with
vitamin D supplementation at 1,000 units/day.
Blood specimens
As outlined in Figure 1, 20 mls of blood was collected in
a Lithium-heparinized tube at baseline, one-month and









Mean Age (yrs) 33.3 ± 7.4 – –
Sex (M:F) 3:13 – –
BMI (kg/m2) 23 ± 3 – –
Vitamin D level
(nmol/L)
















PTH – Parathyroid hormone; Ca – Serum Calcium; CRP – C-reactive Protein.
PTH, Ca & CRP were measured using Beckman Coulter DXC800 Analyser
(Brea, CA). Reference ranges: PTH – 1.7-7 pmol/L, Ca: 2.20-2.60 mmol/L ;
Vitamin D 75–250 nmol/L; CRP 0–5 mg/L. *Value at 1 month compared to
baseline. % at 3 month compared to baseline.
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taken just prior to the first monthly dose, whereas those
at the three-month stage were taken 1 month after the
second monthly dose. Peripheral blood mononuclear
cells (PBMCs) were isolated by Ficoll-gradient centrifuga-
tion and stored in liquid nitrogen for batch stimulation
and flow cytometry. Plasma was also stored at −80°C.
Participants’ vitamin D levels were measured using
the Liaison 25-OH-vitaminD assay (DiaSorin SpA, Saluggia,
Italy), a direct competitive chemiluminescent immunoassay.
Laboratory analysis
Flow cytometry for TLR expression
Two million PBMCs were stained for flow cytometry
with the following anti-human monoclonal antibodies:
anti-TLR2-FITC (clone TLR2.1, eBioscience, San Diego,
CA), anti-TLR4-PE (clone HTA125, eBioscience), anti-
CD14-APC Cy7 (MΦP9, BD Biosciences, San Jose, CA)
and anti-CD86 (clone 2331 FUN-1, BD Biosciences). Ten
thousand CD14positive monocytes were acquired on a BD
FACS Canto. FlowJo software (Treestar, Ashland, OR) was
used for analysis and the geometric mean fluorescence of
each sample was normalized to its own isotype-matched
control.
Cytokine production following in vitro PBMC stimulation
with TLR ligands
PBMCs were rapidly thawed and viability determined
by Trypan Blue exclusion (all samples were greater than
95%). One million PBMCs were stimulated in polystyrene
tubes in 1ml of RPMI-1640 supplemented with 5% Foetal
Calf Serum (FCS) and penicillin / streptomycin containing
either 100 ng/ml Pam3Cys (tripalmitoyl-S-glycerylcysteine,
Invivogen, San Diego, CA), 10 μg/ml PolyI:C (Invivogen),
100 ng/ml LPS (lipopolysaccharide) from Escherichia coli
strain K235 (Sigma Lifesciences), 5 μg/ml R848 (Invivogen),
0.3 μM CpG 2006 or unstimulated (media alone). After
24 hours incubation at 37°C, 5%CO2, 95% humidity,
the supernatants were collected and stored at −20°C for
cytokine ELISA.
Cytokine ELISA
The culture supernatants were assayed using ELISA, for
TNF, IP-10, IL-6 (BD Biosciences, San Jose, CA) and
IFNα (BenderMedSystems, Vienna, Austria) according to
the manufacturers specifications. Assay sensitivities were
8 pg/ml for TNF, IP-10 and IFNα and 5 pg/ml for IL-6.
Statistical methods
We first compared TLR and cytokine levels for partici-
pants who were vitamin D deficient at baseline and
normalised after supplementation to levels >100 nmol/L
at 1 month, (n=11). After this, TLR and cytokine levels
were compared at 1 month and 3 months for thoseparticipants whose vitamin D at 3 months had returned
to deficient levels (n=9). P-values were calculated using
the Wilcoxon Signed Rank Test with a one-sided alpha
of 0.05.
Statistical analysis was carried out using Graphpad
Prism version 5 (Graphpad Software, La Holla, California).Results
Out of 30 healthy staff volunteers, who were a mixture
of doctors, clinical and research laboratory staff, 22
(73%) had a vitamin D level of <50 nmol/L. Baseline
characteristics are shown in Table 1. Of these 22 defi-
cient participants, two were excluded due to abnormal
renal function and four reversed their decision to par-
ticipate. At the end of the three months, 3 participants
were lost to follow up, mainly due to employment
relocation and inconvenience. There were no reported
adverse events as a result of supplementation.
Eleven of those supplemented (61.1%) showed an
excellent response with an increase in the vitamin D
level to >100 nmol/L at one month. Nine of these 11
participants had returned to vitamin D levels below 100
nmol/L at 3 months, despite receiving ongoing vitamin
D supplementation.
As seen in Figure 2, at one month, upon stimulation
of PBMCs with Pam3cys there was increased expression
of TLR2 in participants who reached vitamin D levels
greater than 100 nmol/L upon supplementation (n=11)
and was subsequently reversed at 3 months for those
whose vitamin D had decreased to deficient levels (n=9).
This pattern was not seen in the participants whose peak
vitamin D level reached less than 100 nmol/L (data not
shown). Participant numbers in this group were small,
with only 3 participants following through to testing at 3
Figure 2 TLR2, TLR4 and CD86 expression on Monocytes. TLR 2, TLR4 and CD86 expression, was measured at baseline, 1 and 3 months post
commencement of supplementation, in those who reached peak levels of >100 nmol/L. Geometric mean fluorescence (GMF) was measured by
flow cytometry and normalised to an isotype matched control.
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for CD86 and TLR4 expression.
Figure 3A and 3B demonstrate that, in participants
with levels >100 nmol/L after one month, a statistically
significant drop in TNF and IL-6 levels was seen upon
TLR stimulation with LPS (TLR4 ligand) and Pam3Cys
(TLR2 ligand). This indicates that, although there is no
effect on TLR4 expression, vitamin D modulates the
secretion of these important proinflammatory cytokines.
At 3 months after the pre-load, for those with a reduction
in vitamin D levels, there was a rebound rise in TNF
and IL-6 levels. This drop was also seen for IP10 and
IFNα, although not statistically signsificant.
Discussion
In this small study, we have shown that supplementation
of vitamin D to levels > 100 nmol/L resulted in increased
expression of TLR2 on PBMCs and a reduced TLR2
stimulated cytokine profile for TNFα, IL-6 and IFN-α.
Notably, this pattern reversed quickly when vitamin D
levels reduced to < 100 nmol/L at 3 months after the
initial load with vitamin D supplementation. TLR4 and
CD86 expression were not affected by vitamin D defi-
ciency in our study.
Vitamin D is obtained mostly via cutaneous produc-
tion with ultraviolet B radiation exposure to skin [15]. It
is then further metabolised in the liver and kidney into
its active form 1,25(OH)2D [4]. In assessing vitamin D
status, 25(OH)D levels are mostly measured. Levels can
be affected by multiple factors, including sun exposure,
dietary intake, race, age and BMI [4,16,17]. Hence,reference ranges are controversial, without an absolute
consensus on normal ranges [4,16,18]. It is likely that
ranges will vary for individuals with similar sun ex-
posure, possibly relating to genetic variation in enzyme
activity due to polymorphisms [15]. Vitamin D levels
have also been shown to be inversely related to obesity,
as measured by the BMI [17,19,20]. Some studies of
highly UV-exposed adults have shown low vitamin D
levels in individuals despite similar exposure, with ‘low’
levels potentially being normal for these individuals [4].
However, despite variable reports of prevalence, it has
become commonly accepted that levels below 30 ng/ml
(75 nmol/L) are considered to be suboptimal [4]. For
calcium absorption, it is believed that a level of 80 nmol/L
or higher is optimal [21], whereas for fracture risk, falls,
cancer, insulin sensitivity and potentially immune func-
tion, levels as high as 120 nmol/L may be necessary [21].
One study showed improved sputum conversion and
radiological appearance of tuberculosis infection in those
supplemented with 0.25 mg/day (equivalent to 10,000 IU
of per day) [22]. In a similar study, Martineau et al.
showed the same effect only in participants with the tt
genotype of the TaqI vitamin D receptor polymorphism,
with the mean 25-hydroxyvitamin D level being just
over 100 nmol/L [23]. In another study, respiratory
infections were reduced in African American women
who were receiving 2000 IU per day with serum
levels up to 87 nmol/L [21]. Most experts agree,
based on prior provocative testing and other studies,
that vitamin D deficiency is at levels of <20 ng/mL
(50 nmol/L); insufficiency, 21–29 ng/ml (50 to 75 nmol/L);
Figure 3 Cytokine concentrations upon stimulation with TLR specific ligands, as measured at baseline, 1 and 3 months post start of
vitamin D supplementation. PBMCs were stimulated with TLR ligands LPS (TLR4), Pam3Cys (TLR2), CpG (TLR9) for 24 hours and supernatants
were assayed by cytokine ELISA for TNF (Figure 3A) and IL-6 (Figure 3B). Results were expressed as fold change compared to unstimulated
PBMCs. In Figures 3C and 3D, PBMCs were stimulated with TLR ligands PolyI:C (TLR3) and R848 (TLR7/8) and supernatants were assayed by ELISA
for IP-10 (Figure 3C) and IFNalpha (Figure 3D). Results were expressed by fold change for Figure 3C and absolute values for Figure 3D.
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upper limit of 100 ng/mL (250 nmol/L) [18,24]. Our pilot
study supports levels >100 nmol/L to maintain adequate
innate immune effects, as statistically significant reductions
of proinflammatory cytokines and increased TLR expres-
sion upon stimulation were seen only in study participant
who reached such levels. The increased TLR expression
and the reciprocal reduction in the proinflammatory
cytokine response were lost upon reduction of vitamin D
levels back to below 100 nmol/L.
Mononuclear cells and various other cells in the body,
including prostate, lung and colon cancer cells, contain
1α(OH)ase, the enzymatic machinery required to pro-
duce active vitamin D, which in turn works by binding
to the vitamin D receptor (VDR), a specific nuclear
receptor [8]. VDR is a ligand dependent transcription
factor belonging to the superfamily of steroid, thyroid
hormone and retinoid nuclear receptors [8]. Upon bind-
ing to VDR, the active form of vitamin D results in theproduction of cathelicidin, an antimicrobial peptide in-
volved in the killing of mycobacteria [1]. Prior studies
have shown increased TLR activation after stimulation
of 1α(OH)ase and (VDR) [5,25,26]. Walker et al. showed
that monocytes, derived from cord blood, exhibited
decreased TLR-induced cathelicidin expression when
cultured in vitamin D deficient plasma [27]. Liu et al. had
previously also shown that TLR activation up-regulated
VDR expression and subsequent induction of cathelicidin
[26]. Lack of vitamin D, VDR or 1α(OH)ase blunts the
macrophages ability to produce antimicrobial peptides [2].
While multiple studies have looked at the role of
TLR2 and TLR4 activation on the expression of VDR
and cathelicidin, few are available on the effect of vita-
min D on TLR activation. Do et al. showed, in a cross
sectional study of patients with Behçet’s disease, an
inverse correlation between the expression of TLR2 and
TLR4 and vitamin D levels. Additonally, in vitro, they
demonstrated that vitamin D3 was able to suppress
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[9]. In contrast, our study showed an increase in TLR2
expression upon supplementation of vitamin D to levels
above 100 ng/mL (250 nmol/L). This fits with the hypoth-
eses that vitamin D is an immune modulator which varies
in its effect based on the presence of inflammation. In the
setting of Behçet’s, an inflammatory condition, vitamin D
may act as a down regulator of inflammatory responses,
resulting in reduced TLR expression. In healthy subjects,
vitamin D may heighten TLR expression, in preparation
for possible pathogen encounters. These hypotheses need
to be investigated further, ideally in a large study which
includes both healthy subjects and patients with other
conditions, including chronic inflammatory conditions
and chronic infections. There is recent evidence that
vitamin D’s immunomodulatery effect is in part due to
the presence of VDR on inflammatory cells and the
ability of macrophages and dendritic cells to produce the
active form of vitamin D in the presence of CYP27B1
(1αhydroxylase) [28]. In these cells however, the enzyme
is stimulated by cytokines rather than parathyroid
hormone, which stimulates this enzyme in the kidney
[28]. Stimulation of TLR2 has been shown to result in
increased expression of CYP27B1 [25].
Mahon et al. previously investigated the association
between vitamin D and cytokine production while exam-
ining the effect of vitamin D supplementation in multiple
sclerosis patients [26]. They found that supplementation
significantly increased transforming growth factor (TFG)-
β1, an anti-inflammatory cytokine, without a significant
difference in TNF-α and IFNγ levels [29]. However, vita-
min D levels in their subjects were below recommended
levels despite supplementation [29], limiting interpretation
of their results.
There are a number of limitations to our study. As a
pilot study, the sample size was small. However, with
repeated measures of both vitmain D levels and innate
immune markers, we were able to efficiently use our data
to demonstrate reversible changes in innate immunity
when vitamin D levels changed from deficient to normal.
In order to be able to properly assess the impact of
different vitamin D serum levels and to explore further
whether supplementation of the vitamin to levels >100
nmol/L is optimal, a larger study, with a similar repeated
measures design which lends itself to investigating the
reversability of vitamin D’s effect on TLR expression
and cytokine production, is required. It would be import-
ant to objectively assess adherence to supplementation,
such as pill-count or direct observed therapy protocols.
Our study relied on word-of-mouth and may have thus
been influenced by non-adherence. It would also be
worthwhile to include patients with chronic inflammatory
conditions and infections, in order to assess if vitamin D
supplementation in these patients affects their cytokineprofile. Another relevant question not addressed by this
study is the clinical and functional significance of these
findings. A larger study with longer supplementation and
follow-up periods, allowing monitoring for rates infection
or inflammatory conditions, may have permitted analysis
of the potential clinical relevance of the demonstrated
increase in expression of TLR2. This would have been
made more relevant by comparison to an unsupplemented
control group with variable vitamin D levels. In this study,
an attempt was made to look at the functional meaning
of the increased expression of TLR2 activation by looking
at cytokine production. It would also be of interest to ex-
pand the study further in order to explore the molecular
mechanisms behind our findings.
Conclusions
While this is a small, pilot study, we have shown for the
first time in humans that optimal vitamin D levels after
supplementation may improve the expression of TLR2
and hence the body’s ability to fight infections. We have
also demonstrated a marked reduction in the induced
cytokine profile, specifically IL6, TNF and IFN alpha
associated with higher vitamin D levels and the revers-
ibility of the innate immune profile with decreasing
levels. There are multiple implications for this, including
the potential role for vitamin D to dampen down the
innate immune system in autoimmune conditions. In
addition, there may be a role for vitamin D as a modula-
tor of immune response to vaccines. To help further
delineate the benefits of vitamin D and its role in vivo,
larger, randomised, double-blinded, controlled studies
with broader sampling of subjects, including those with
inflammatory conditions, are required.
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